A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer

In October 2016, pembrolizumab became the new standard of care for firstline treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death ligand 1 in at least 50% of cells. The US Food and Drug Administration-recommended dose is 200 mg every three w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 2017-11, Vol.109 (11)
Hauptverfasser:	Goldstein, Daniel A, Gordon, Noa, Davidescu, Michal, Leshno, Moshe, Steuer, Conor E, Patel, Nikita, Stemmer, Salomon M, Zer, Alona
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - economics Antineoplastic Agents - administration & dosage Antineoplastic Agents - economics B7-H1 Antigen - metabolism Body Weight Budgets Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - secondary Disease-Free Survival Drug Costs Drug Dosage Calculations Humans Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Lung Neoplasms - mortality Lung Neoplasms - pathology Monte Carlo Method Precision Medicine - economics United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!